and leading indication for liver transplantation in the United States (3) (4) (5) (6) . Sex diff erences in NAFLD epidemiology are recognized. While isolated steatosis is more common in men, women have higher rates of NASH, with an estimated 15 million United States women aff ected ( 3, 7, 8 ) . To prevent liver-related deaths due to NASH cirrhosis, there is an urgent need to understand key risk factors for NAFLD development and progression in women.
Th ere is growing recognition that young women with hyperandrogenism represent a high-risk group for NAFLD ( 2 ) . Th e mechanism by which androgens may promote hepatic steatosis in women is not well-defi ned, though increasing testosterone levels in middle-aged women are associated with higher visceral adipose tissue (VAT) volume, a known risk factor for NAFLD ( 2, 9 ) . Small studies among young hyperandrogenic women demonstrate higher prevalence of ultrasound-confi rmed steatosis and liver enzyme elevation, independent of body mass index (BMI) and insulin resistance ( 10 ) . Larger studies evaluating the association between androgens and NAFLD among pre-menopausal women are lacking. It remains unknown whether testosterone is associated with NAFLD independent of metabolic derangements, or whether testosterone is associated with NAFLD among women without hyperandrogenism.
Using data from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort, we aimed to evaluate the association of free testosterone measured in pre-menopausal years on risk of prevalent NAFLD in midlife. We hypothesized that testosterone levels would be associated with prevalent NAFLD in a broad population of women, including those without hyperandrogenism, independent of metabolic factors. If this association were identifi ed, testosterone could represent a novel biomarker of NAFLD in pre-menopausal women, while also providing a potential novel target for therapeutic intervention.
METHODS

Study population
We utilized data from the CARDIA cohort ( 11, 12 ) , and the CARDIA Women's Study (CWS) ( 13, 14 ) , an ancillary study to CARDIA. Th e CARDIA cohort is a multicenter community-based longitudinal study of cardiovascular disease in young African American and Caucasian adults aged 18-30 years. Participants were initially recruited in 1985-1986 from 4 cities across the United States (Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA) with the intent to enroll equal proportions of African Americans and Caucasians. Subsequent follow-up occurred at Years 2, 5, 7, 10, 15, 20 , and 25, with a 72% retention rate by Year 25. Th e initial cohort included n =5115 participants, of whom n =2790 (55%) were women. Participants were recruited by random-digit dialing from total communities, census tract information, or health-care plan as previously described ( 11 ) . Institutional review board approval was obtained from all participating centers.
From the initial cohort of CARDIA women ( n =2790) we included those that underwent computed tomography (CT) quantifi cation of hepatic steatosis at the Year 25 follow-up examination ( n =1805). We excluded women with other potential causes of hepatic steatosis including alcohol use>2 drinks/day ( n =79), selfreport of other causes of chronic liver disease ( n =18), those with HIV ( n =4), and those with history of medication use associated with steatosis, including amiodarone, methotrexate, valproic acid, tamoxifen, steroids, diltiazem, or hormone replacement therapy ( n =23). We then excluded women lacking Year 2 androgen measurements ( n =629), for a fi nal study sample of n =1052 ( Figure 1 ). Baseline characteristics of women meeting inclusion and exclusion criteria were similar, with statistically signifi cant, though not clinically meaningful diff erences for age, race, HDL, and triglyceride levels between groups ( Supplementary Table 1 online).
Measurements
Androgens . Androgen levels were measured as part of the CAR-DIA Women's Study from stored fasting serum samples collected at Year 2 (1987 Year 2 ( -1988 , Year 10 (1997 Year 10 ( -1998 , and Year 16 (2003 Year 16 ( -2004 . Blood draws targeted the follicular phase of the menstrual cycle ( 13 ) . Measurements included total testosterone, free testosterone, and sex hormone binding globulin (SHBG) performed at the Obstetrics and Gynecology Research and Diagnostic Laboratory at the University of Alabama, Birmingham. Total testosterone was measured with a competitive immunoassay (Beckman Coulter, Fullerton, CA) using direct chemiluminescence on the Beckman Access Automated System and SHBG was determined using equilibrium analysis. Total testosterone and SHBG levels were then used to calculate free testosterone, or biologically active testosterone levels ( 15 ) . Free testosterone levels were measured at Year 2 ( n =1049) and in a smaller sample of women at Year 10 ( n =974) and Year 16 ( n =778). Th ere was a signifi cant correlation between Year 2, 10 and 16 free testosterone measurements (correlation of 0.52 between Years 2 and 10, and 0.45 between Years 2 and 16, P -values <0.001). Year 2 free testosterone was chosen as the primary predictor because these values were available on the largest sample of women and refl ect values obtained during pre-menopause, with median age of 28 years (IQR [25] [26] [27] [28] [29] [30] . Testosterone levels are known to decline with menopausal transition 
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Testosterone Levels and NAFLD Risk in Women while levels remain relatively stable throughout a woman's premenopausal years ( 16, 17 ) . In a sensitivity analysis, we evaluated the association of Year 10 free testosterone with prevalent NAFLD to confi rm the consistency of estimates using another timepoint from pre-menopausal years. (19) (20) (21) . Th e characterization of LA in this cohort used a dedicated workfl ow within the National Institute of Health's Center of Information Technology Medical Image Processing, Analysis, and Visualization application has been previously described ( 22 ) . Th e interclass correlation coeffi cient between diff erent readers on a random sample of 156 participants was 0.975 for LA, indicating high reproducibility of CT-measured LA in this cohort ( 22 ) .
Covariates . Participant demographics, medical history, and alcohol use were obtained through standardized surveys as previously described in CARDIA ( 11 ) . Race was defi ned as African American or Caucasian by self-report. Medication use was obtained by self-report and subsequent verifi cation of medications brought to study visits. Standard protocols were employed for fasting serum collection and assays of plasma triglycerides (TG), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), total cholesterol (TC), serum glucose and insulin levels ( 23, 24 ) . Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated using the equation: [fasting glucose (mmol/l)×fasting insulin (mU/l)]/22.5. Th ese serum measures were analyzed from baseline and Year 25. Diabetes history was defi ned as fasting glucose≥126 mg/dl or 2 h glucose tolerance test≥200 mg/dl or hemoglobin HbA1c≥6.5% or use of diabetic medications in the absence of pregnancy at any study visit in CARDIA. Certifi ed technicians performed anthropometric measurements including weight, height and waist circumference using standardized protocols, and BMI calculated as weight (kg)/height (m) 2 . Waist circumference was measured midway between the iliac crest and bottom of the rib cage. Th ese anthropomorphic measures were also analyzed from baseline and Year 25 visits. Visceral adiposity tissue (VAT) volume was measured on the Year 25 CT scan and refl ects the sum of fat voxels within 10 mm set of slices centered at the L4-5 disk within the intraabdominal cavity. Interclass correlation coeffi cient for the inter-reader comparisons were 0.989 for VAT, and intra-and inter-reader error were 2.4% and 6.7%, respectively in 156 scans aft er blinded re-evaluation ( 25 ) .
Statistical analysis
Baseline (Year 0) and Year 25 characteristics were compared using chi-square and Mann-Whitney U tests where appropriate. Baseline measurements were selected for all analyses instead of Year 2 due to missing covariate measurements at Year 2, and good correlation between Year 0 and next available measurements. BMI and waist circumference were not measured at Year 2, though baseline and Year 5 measurements were highly correlated (correlation 0.86-0.89, P <0.001). HOMA-IR was performed at baseline, then not again until Year 7, although even baseline and Year 7 HOMA-IR values were signifi cantly correlated (correlation 0.45, P <0.001). Lipid measurements were missing in 10-15% of the cohort at Year 2, though total cholesterol, LDL, HDL, and triglycerides at baseline and Year 2 were also highly correlated (correlation values of 0.61-0.68, P values <0.001).
Logistic regression was used to evaluate the association of quintiles of free testosterone at Year 2 and prevalent NAFLD at Year 25. Bivariate models assessed the association of covariates chosen a priori for clinical relevance and known associations with NAFLD. Covariates included age, race, and metabolic parameters including BMI, waist circumference, total cholesterol, LDL, HDL, triglycerides, and insulin resistance (HOMA-IR). To better capture the longitudinal eff ects of covariates on prevalent NAFLD, metabolic factors were analyzed at baseline as well as change from baseline to Year 25. Th e fi nal multivariate model was developed using forward selection of covariates including those with two sided P -values<0.05, or strong biologic justifi cation for inclusion. To evaluate the association of VAT (available only at Year 25) and NAFLD, the covariates identifi ed in the fi nal model were evaluated in a separate model using only Year 25 measurements. Finally, triglycerides, HOMA-IR and VAT volume were evaluated as mediators of free testosterone and NAFLD using the STATA mediation package ( 26 ) , given their potential role along the causal pathway from testosterone to NAFLD in hyperandrogenic women ( 27 ) . Th is approach employs regression analyses to capture direct and indirect mediating eff ects of key variables. Eff ect modifi cation of these covariates was evaluated by adding the cross-product interaction terms to the fi nal model, with P -values ≤0.10 used to identify statistically signifi cant interactions. Analyses were performed using STATA 12.1 (StataCorp, College Station, TX).
RESULTS
Study cohort characteristics
Of the 1052 women meeting inclusion criteria, 49.6% were African American, with median ages at baseline and Year 25 of 26 years (IQR 23-28) and 51 years (IQR 48-53), respectively. Metabolic co-morbidities were more severe at Year 25 than at study entry including higher median BMI, waist circumference, HOMA-IR, total cholesterol, LDL, and triglycerides ( Table 1 ) . At study entry <1% of women had diabetes compared to nearly 13% with this diagnosis by Year 25. Among women with diabetes, 30.1% reported oral agent and/or insulin use. Most women (80.3%) had a history of hormonal contraception use.
Eighty-nine (8.5%) women met CT defi nition for NAFLD at Year 25. Compared to women without NAFLD, women with NAFLD had higher baseline and Year 25 BMI, waist circumference, triglycerides, and HOMA-IR, and higher Year 2 free testosterone levels ( P values≤0.01). At Year 25, NAFLD women also had lower HDL, higher VAT volume, and were more likely to have diabetes ( P <0.001). Racial distribution was not signifi cantly diff erent between groups ( Supplementary Table 2 ).
Median free testosterone levels at Years 2 and 10 were 0.23 ng/ dl (IQR 0.13-0.36) and 0.20 ng/dl (IQR 0.11-0.32), respectively, which were signifi cantly correlated ( ρ =0.52). Th is is consistent with the expected stability of free testosterone levels during premenopausal years ( 16, 17 ) . Free testosterone levels were lower by Year 16 with a median value of 0.15 ng/dl, refl ecting decline in androgen production as women approach peri-menopausal years ( 16 ) . Total testosterone and SHBG levels showed similar decline from Years 2 to 16 (test of trend P <0.001) ( Table 2 ). Approximately 6% ( n =65) of women in this study met criteria for hyperandrogenism using Year 2 free testosterone, which included n =50 women with a diagnosis of PCOS ( 18 ) . Only n =24 women (2.3%) had history of spironolactone use, most of whom carried a diagnosis of PCOS. Hyperandrogenic women were slightly younger, more likely to be African American, and had higher baseline and Year 25 BMI and waist circumference than non-hyperandrogenic women. Th ey also had higher levels of Year 25 LDL, HOMA-IR, and VAT volume, although these diff erences were not statistically signifi cant ( Supplementary Table 3 ).
Free testosterone and prevalent NAFLD
We fi rst evaluated whether free testosterone measured at Year 2 was associated with prevalent NAFLD at Year 25 in unadjusted analysis. Increasing quintiles of free testosterone conferred a nearly 30% increased odds of NAFLD (odds ratio (OR) 1.29, 95% confi dence interval (CI) 1.10-1.51, P =0.001). Most metabolic cofactors were also associated with NAFLD on unadjusted analysis, including higher baseline BMI, waist circumference, triglycerides, as well as baseline HOMA-IR. Change from Year 0 to Year 25 BMI, waist circumference, triglycerides, HDL, and HOMA-IR were also associated with NAFLD ( Table 3 ) . Th ere was a trend towards a 
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(AOR 1.14, 95% CI 0.87-1.49, P =0.337). We then performed sensitivity analyses excluding the n =65 women (6.2%) meeting criteria for hyperandrogenism ( 18 ) . Importantly, Year 2 free testosterone remained associated with prevalent NAFLD among non-hyperandrogenic women (AOR 1.27, 95% CI 1.05-1.53, P =0.016). We further evaluated whether Year 2 free testosterone was associated with NAFLD when only considering baseline covariates, refl ecting an age that preceded the development of metabolic co-morbidities in the majority of women. Year 2 free testosterone was strongly associated with prevalent NAFLD, independent of baseline triglycerides and waist circumference (AOR 1.24, 95% CI 1.05-1.46, P =0.013; Supplementary Table 4 ). Finally, we assessed the association of free testosterone with prevalent NAFLD using only Year 25 covariates, which refl ect values obtained from the same year as NAFLD diagnosis. VAT volume was measured on Year 25 CT and used in place of waist circumference in Year 25 models given the high correlation of Year 25 waist circumference and VAT volume (correlation 0.74, P -value <0.001). On unadjusted analysis, most Year 25 metabolic covariates were associated with NAFLD, with VAT, HOMA-IR, and triglycerides remaining signifi cant in the multivariate model ( Supplementary Table 5a ).
protective eff ect of hormonal contraception on univariate ana lysis, although this was not signifi cant on adjusted analysis (adjusted odds ratio (AOR) AOR 0.68, 95% CI 0.39-1.19, P =0.178).
On multivariate analyses, increasing quintiles of free testosterone remained independently associated with NAFLD (AOR 1.25, 95% CI 1.04-1.50, P =0.015), aft er adjustment for baseline and change in waist circumference, HOMA-IR, and triglycerides. BMI and HDL were no longer associated with NAFLD on adjusted analysis ( Table 3 ) . Although age and race have known associations with NAFLD risk ( 2 ), forcing these covariates into the adjusted model minimally aff ected free testosterone estimates (AOR 1.24, 95% CI 1.04-1.49, P =0.020). In a sensitivity analysis using the smaller number of women with Year 10 free testosterone ( n =974), the strength of the association with prevalent NAFLD was similar on unadjusted analysis (OR 1.36, 95% CI 1.15-1.61, P <0.001) and aft er adjustment for the same metabolic parameters as the Year 2 model (AOR 1.22, 95% CI 1.00-1.48, P =0.050). Even fewer women had repeat hormone values at Year 16 ( n =778), with similar association on unadjusted analysis (OR 1.45, 95% CI 1.14-1.84, P <0.001). Although the direction of the association remained consistent on adjusted analysis, this was no longer signifi cant To explore the mechanism by which testosterone may contribute to NAFLD we conducted formal testing for mediation using Year 25 covariates ( 26 ) . As expected, VAT was confi rmed to be a significant mediator, with 41.0% (95% CI 21.7-119.3%) of the observed association of free testosterone on prevalent NAFLD attributed to VAT volume. Year 25 triglyceride levels were also a statistically signifi cant mediator, although with smaller estimated mediating eff ect of 12.1% (95% CI 2.8-37.8%). HOMA-IR did not appear to mediate the association of free testosterone and NAFLD (mediating eff ect of 12.9%, 95% CI −4.7-41.2%).
Th ere was a statistically signifi cant interaction between Year 25 HOMA-IR and free testosterone ( P <0.001) suggesting that the association between free testosterone and NAFLD may vary by degree of insulin resistance. However, the association of free testosterone and NAFLD by level of HOMA-IR could not be further explored because all but 7 women with NAFLD also had insulin resistance (defi ned as HOMA-IR≥2) by Year 25. We also assessed for interactions between free testosterone and race given a higher proportion of African Americans in the subgroup of hyperandrogenic women ( Supplementary Table 3 ), but no signifi cant interaction was identifi ed ( P =0.14).
DISCUSSION
Using data from the large prospectively collected CARDIA cohort we identifi ed an association of free testosterone measured in premenopausal women on risk of prevalent NAFLD in midlife. Th is association was independent of comprehensive metabolic parameters including anthropomorphic measures, lipids, and insulin resistance. Importantly, the association of free testosterone with prevalent NAFLD was apparent even in non-hyperandrogenic women, indicating a broader role of testosterone in the pathogenesis of NAFLD that extends beyond the well-recognized subgroup of women with androgen excess. Visceral adiposity was also identifi ed as a strong, partial mediator of this association, suggesting a potential causal role of VAT along the pathway from androgens to NAFLD in women.
Prior data investigating androgens in NAFLD have largely focused on hyperandrogenic women with the common endocrinopathy known as Polycystic Ovary Syndrome (PCOS) ( 28 ) . Indeed half of these hyperandrogenic women have imaging confi rmed steatosis and concurrent liver enzyme elevation (29) (30) (31) . Th e current study represents an important advance in our understanding of testosterone and NAFLD, by highlighting the association of pre-menopausal testosterone levels with subsequent risk of prevalent NAFLD, even in women without androgen excess. Although the onset of NAFLD could not be ascertained in our cohort, it is unlikely that women in their 20 s without metabolic co-morbidities had NAFLD at baseline, particularly during a time period that pre-dated the onset of the obesity and diabetes epidemics (1987) (1988) ( 32 ) . Th e strong correlation between Year 2 and Year 10 free testosterone measurements also supports a stability of androgen elevation during pre-menopausal years that may set the stage for NAFLD development in later life.
Th e mechanism by which testosterone promotes NAFLD is likely multifactorial. Visceral adiposity, and to a lesser degree, hypertriglyceridemia, were found to be signifi cant mediators of the association between testosterone and NAFLD, suggesting an important role of VAT in this relationship. Th ese observations are consistent with clinical data noting that administration of synthetic testosterone increases visceral adiposity among post-menopausal women ( 33 ) . Androgens have also been shown to directly regulate lipid metabolism within visceral and subcutaneous adipocytes in women ( 34 ) . Rats exposed to high dose androgens during pre-natal periods demonstrate alterations in adipocyte lipolysis, hepatic lipid metabolism and glucose intolerance, and these metabolic derangements are sustained into puberty and adulthood ( 34, 35 ) . Th ese data support the longstanding eff ects of early androgen exposure on subsequent risk of metabolic syndrome, and may help to explain the strong mediating eff ects of VAT and serum triglycerides identifi ed in the current study. Surprisingly, insulin resistance was not found to be a signifi cant mediator of the association of free testosterone and NAFLD although we did rely on HOMA-IR, a less sensitive measure of insulin resistance than gold standard euglycemic hyperinsulinemic clamp measurements ( 36 ) .
Our fi ndings raise the intriguing question as to whether antiandrogen therapy could help to prevent NAFLD in women, or reverse existing disease. In hyperandrogenic women, insulin resistance assessed by clamp measurements improves with spironolactone treatment, an androgen receptor antagonist ( 37 ) . Spironolactone also increases glucose uptake in human adipocytes ( 38 ) , supporting a role of androgens in peripheral insulin resistance. Impressively, data from mouse models of diet-induced diabetes and NAFLD found that spironolactone treatment decreased serum free fatty acids and hepatic triglycerides, improved serum lipids as well as NASH histology. Spironolactone further induced hepatocyte expression of lipogenic enzymes, supporting a more direct role of androgen receptors within hepatocytes on lipid metabolism ( 39 ) . Likewise, short course spironolactone trials in humans have shown decreased visceral adiposity ( 40 ) and serum free fatty acids ( 41 ) . Taken together, these data suggest that anti-androgen therapy may help to improve metabolic co-morbidities, and their role in NAFLD development and progression in women may warrant exploration.
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WHAT IS NEW HERE
✓ Testosterone levels in healthy young women are independently associated with risk of NAFLD in midlife.
✓ Testosterone is associated with NAFLD risk, even in women without androgen excess.
sex-based models of care in NAFLD. Testosterone may also provide a novel target for therapeutic intervention in men with NAFLD, albeit with potentially opposite goals of hormone modulation.
Th e current study has important strengths and some notable limitations. Th e CARDIA cohort includes a large, well-characterized population of Caucasian and African American women with detailed metabolic parameters followed for more than 2 decades, though lack of reported Hispanic ethnicity limits generalizability to Latina populations. Given the lack of liver pathology and hepatic enzyme measurements, the association of androgens with nonalcoholic steatohepatitis in women could not be addressed. CT imaging was also unavailable at baseline therefore the timing of NAFLD development could not be ascertained. However, as noted above we do believe our fi ndings support an association of free testosterone on risk of developing NAFLD, as sex hormones were measured in healthy young women without metabolic disease, that were recruited prior to the onset of the obesity and diabetes epidemics. We defi ned NAFLD by liver attenuation (LA) cutoff s that were based on prior data showing excellent specifi city, though lower sensitivity, for histologically confi rmed NAFLD ( 19 ) . Higher specifi city minimizes the eff ect of measurement bias ( 50 ) , although this comes at a cost of decreased NAFLD detection for those with mild degrees of steatosis, which likely explains the low prevalence of NAFLD in our cohort. Magnetic resonance imaging is more sensitive for detecting earlier grades of steatosis ( 51 ) , and would have likely increased the number of women with NAFLD, though this imaging modality was not available. Although the current study was limited to free testosterone measurements in pre-menopausal women, a recent cross sectional study identifi ed a strong and independent association of increasing quartiles of testosterone with hepatic steatosis in post-menopausal women ( 52 ) . Th erefore testosterone is likely an important risk factor for NAFLD among women across reproductive age. Finally, a notable strength of our study was the robust statistical approach to evaluate potential mediators, which allowed us to identify the signifi cant role of VAT, and to a lesser degree, that of serum triglycerides, on the relationship between testosterone and NAFLD in women.
In conclusion, we identifi ed a novel association of free testosterone measured in pre-menopausal years on subsequent risk of prevalent NAFLD in midlife within a large cohort of United States women. Importantly, this association was present even among women without androgen excess , suggesting a role of testosterone on NAFLD risk in a broader spectrum of women. Further mechanistic studies should explore androgen receptors in the liver including their role in glucose and lipid homeostasis, in an eff ort to expand targets for NAFLD therapeutics in women.
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